Compare Stocks: VERO, NXL, BBLG, and VRAX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBLG Bone Biologics	$0.38 -4.5%	$0.52	$0.37 ▼ $2.39	$1.09M	0.9	34,553 shs	25,825 shs
NXL Nexalin Technology	$1.71 -8.1%	$5.46	$1.65 ▼ $49.50	$1.36M	4.08	3.28 million shs	51,719 shs
VERO Venus Concept	$0.31	$0.31	$0.25 ▼ $12.93	$442K	-0.06	2.28 million shs	N/A
VRAX Virax Biolabs Group	$1.19 -2.5%	$2.36	$1.15 ▼ $21.75	$970K	1.4	207,309 shs	10,468 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBLG Bone Biologics	0.00%	-0.05%	-20.40%	-61.48%	-82.38%
NXL Nexalin Technology	0.00%	-20.85%	-58.94%	-85.97%	-95.69%
VERO Venus Concept	0.00%	0.00%	0.00%	0.00%	-86.08%
VRAX Virax Biolabs Group	0.00%	-15.86%	-48.74%	-60.65%	-91.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBLG Bone Biologics	$0.38 -4.5%	$0.52	$0.37 ▼ $2.39	$1.09M	0.9	34,553 shs	25,825 shs
NXL Nexalin Technology	$1.71 -8.1%	$5.46	$1.65 ▼ $49.50	$1.36M	4.08	3.28 million shs	51,719 shs
VERO Venus Concept	$0.31	$0.31	$0.25 ▼ $12.93	$442K	-0.06	2.28 million shs	N/A
VRAX Virax Biolabs Group	$1.19 -2.5%	$2.36	$1.15 ▼ $21.75	$970K	1.4	207,309 shs	10,468 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBLG Bone Biologics	0.00%	-0.05%	-20.40%	-61.48%	-82.38%
NXL Nexalin Technology	0.00%	-20.85%	-58.94%	-85.97%	-95.69%
VERO Venus Concept	0.00%	0.00%	0.00%	0.00%	-86.08%
VRAX Virax Biolabs Group	0.00%	-15.86%	-48.74%	-60.65%	-91.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBLG Bone Biologics	1.00	Sell	N/A	N/A
NXL Nexalin Technology	1.50	Reduce	N/A	N/A
VERO Venus Concept	1.00	Sell	N/A	N/A
VRAX Virax Biolabs Group	2.00	Hold	$25.00	2,000.84% Upside

Current Analyst Ratings Breakdown

Latest VERO, NXL, BBLG, and VRAX Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/22/2026	BBLG Bone Biologics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/2/2026	VRAX Virax Biolabs Group	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/1/2026	NXL Nexalin Technology	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
9/25/2026	NXL Nexalin Technology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/9/2026	NXL Nexalin Technology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	NXL Nexalin Technology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBLG Bone Biologics	N/A	N/A	N/A	N/A	$3.00 per share	N/A
NXL Nexalin Technology	$300K	4.16	N/A	N/A	$6.03 per share	0.28
VERO Venus Concept	$58.88M	0.01	N/A	N/A	$4.30 per share	0.07
VRAX Virax Biolabs Group	$10K	95.20	N/A	N/A	$42.23 per share	0.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBLG Bone Biologics	-$3.11M	-$1.37	N/A	N/A	N/A	N/A	-57.87%	-53.65%	11/13/2026 (Estimated)
NXL Nexalin Technology	-$8.22M	-$14.41	N/A	N/A	N/A	-4,141.94%	-278.24%	-218.42%	11/13/2026 (Estimated)
VERO Venus Concept	-$47M	-$48.84	N/A	N/A	N/A	-92.76%	-1,904.25%	-85.22%	N/A
VRAX Virax Biolabs Group	-$5.02M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	12/2/2026 (Estimated)

Latest VERO, NXL, BBLG, and VRAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	N/A	BBLG Bone Biologics	-$0.19	N/A	N/A	N/A	N/A	N/A
11/13/2026	Q3 2026	NXL Nexalin Technology	-$2.91	N/A	N/A	N/A	$0.08 million	N/A
10/26/2026	Q3 2026	BBLG Bone Biologics	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
8/14/2026	Q2 2026	BBLG Bone Biologics	-$0.39	-$0.43	-$0.04	-$0.43	N/A	N/A
8/12/2026	Q2 2026	NXL Nexalin Technology	-$3.00	-$0.11	+$2.89	-$3.30	$0.09 million	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBLG Bone Biologics	N/A	N/A	N/A	N/A	N/A
NXL Nexalin Technology	N/A	N/A	N/A	N/A	N/A
VERO Venus Concept	N/A	N/A	N/A	N/A	N/A
VRAX Virax Biolabs Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBLG Bone Biologics	N/A	8.67	8.67
NXL Nexalin Technology	N/A	1.25	1.10
VERO Venus Concept	1.59	0.90	0.59
VRAX Virax Biolabs Group	N/A	9.97	9.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBLG Bone Biologics	34.30%
NXL Nexalin Technology	0.65%
VERO Venus Concept	87.41%
VRAX Virax Biolabs Group	8.61%

Insider Ownership

Company	Insider Ownership
BBLG Bone Biologics	5.00%
NXL Nexalin Technology	16.94%
VERO Venus Concept	28.04%
VRAX Virax Biolabs Group	45.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBLG Bone Biologics	2	2.76 million	2.62 million	Not Optionable
NXL Nexalin Technology	8	730,000	610,000	Not Optionable
VERO Venus Concept	410	1.42 million	1.03 million	Not Optionable
VRAX Virax Biolabs Group	26	800,000	438,000	Not Optionable

VERO, NXL, BBLG, and VRAX Headlines

Recent News About These Companies

Virax Biolabs Restructures Leadership to Prioritize ViraxImmune Development

October 9, 2026 | tipranks.com

Virax Biolabs Expands ATM Share Offering With New SEC Filing

September 4, 2026 | tipranks.com

Virax Biolabs Shareholders Approve Major Capital Increase but Reject Governance Overhaul

August 26, 2026 | tipranks.com

Join Virax’s Live Investor Webinar: Advancing Immune Diagnostics, Clinical Development and Commercial Execution

August 20, 2026 | usatoday.com

Virax Biolabs Calls August 14 EGM to Approve Major Share Capital Increase

August 2, 2026 | theglobeandmail.com

RedChip Companies, Inc.: Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big Money Show on Bloomberg TV

July 20, 2026 | finanznachrichten.de

Virax Biolabs Boosts Liquidity, Secures Fosun Deal and Restores Nasdaq Compliance After Fiscal 2026 Report

July 17, 2026 | tipranks.com

Virax BioLabs Group Limited: Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

July 16, 2026 | finanznachrichten.de

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

July 16, 2026 | prnewswire.com

Virax Biolabs Raises $3.3 Million via Exercise of Investment Options and Issues New Warrants

July 10, 2026 | tipranks.com

Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

July 10, 2026 | prnewswire.com

Virax Biolabs Group Limited Ordinary Shares (VRAX) Institutional Holdings

July 10, 2026 | nasdaq.com

Virax Biolabs stock skyrockets 100% on exclusive distribution agreement

July 9, 2026 | msn.com

Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

July 9, 2026 | prnewswire.com

Virax Biolabs shares double after exclusive Fosun distribution agreement (VRAX)

July 9, 2026 | msn.com

Why this biotech stock more than tripled on Thursday

July 9, 2026 | invezz.comI

Virax Biolabs Jumps on Fosun Diagnostics Supply Agreement

July 9, 2026 | quiverquant.comQ

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics

July 9, 2026 | prnewswire.com

Virax Biolabs Group announces 1-for-25 share consolidation

June 25, 2026 | msn.com

Virax Biolabs Approves 1-for-25 Share Consolidation to Maintain Nasdaq Listing

June 24, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO, NXL, BBLG, and VRAX Company Descriptions

Bone Biologics NASDAQ:BBLG

$0.38 -0.02 (-4.51%)

Closing price 04:00 PM Eastern

Extended Trading

$0.38 +0.00 (+1.06%)

As of 07:30 PM Eastern

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Nexalin Technology NASDAQ:NXL

$1.71 -0.15 (-8.06%)

Closing price 04:00 PM Eastern

Extended Trading

$1.72 +0.01 (+0.70%)

As of 07:43 PM Eastern

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

Venus Concept NASDAQ:VERO

$0.31 0.00 (0.00%)

As of 10/23/2026

Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.

Virax Biolabs Group NASDAQ:VRAX

$1.19 -0.03 (-2.46%)

Closing price 03:46 PM Eastern

Extended Trading

$1.16 -0.02 (-2.10%)

As of 07:30 PM Eastern

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VERO, NXL, BBLG, and VRAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VERO, NXL, BBLG, and VRAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VERO, NXL, BBLG, and VRAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO, NXL, BBLG, and VRAX Company Descriptions

Bone Biologics NASDAQ:BBLG

Nexalin Technology NASDAQ:NXL

Venus Concept NASDAQ:VERO

Virax Biolabs Group NASDAQ:VRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VERO, NXL, BBLG, and VRAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VERO, NXL, BBLG, and VRAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VERO, NXL, BBLG, and VRAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO, NXL, BBLG, and VRAX Company Descriptions

Bone Biologics NASDAQ:BBLG

Nexalin Technology NASDAQ:NXL

Venus Concept NASDAQ:VERO

Virax Biolabs Group NASDAQ:VRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools